At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
In Brief
A Phase 2 clinical trial evaluating 24 valent pneumococcal conjugate vaccine and 20 valent pneumococcal conjugate vaccine for Pneumococcal Vaccines. Completed, enrolled 835 participants across 13 sites.
Detailed Summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Study Details
Timeline
Interventions
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1